Literature DB >> 15530989

1-Deoxy-D-xylulose 5-phosphate reductoisomerase: an overview.

Philip J Proteau1.   

Abstract

The methylerythritol phosphate pathway to isoprenoids, an alternate biosynthetic route present in many bacteria, algae, plants, and the malarial parasite Plasmodium falciparum, has become an attractive target for the development of new antimalarial and antibacterial compounds. The second enzyme in this pathway, 1-deoxy-D-xylulose 5-phosphate reductoisomerase (DXR; EC 1.1.1.267), has been shown to be the molecular target for fosmidomycin, a promising antimalarial drug. This enzyme converts 1-deoxy-D-xylulose 5-phosphate (DXP) into the branched compound 2-C-methyl-D-erythritol 4-phosphate (MEP). The transformation of DXP into MEP requires an isomerization, followed by a NADPH-dependent reduction. The discovery of DXR, its subsequent characterization, and the identification of inhibitors will be presented.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15530989     DOI: 10.1016/j.bioorg.2004.08.004

Source DB:  PubMed          Journal:  Bioorg Chem        ISSN: 0045-2068            Impact factor:   5.275


  22 in total

1.  Toward Mycobacterium tuberculosis DXR inhibitor design: homology modeling and molecular dynamics simulations.

Authors:  Nidhi Singh; Mitchell A Avery; Christopher R McCurdy
Journal:  J Comput Aided Mol Des       Date:  2007-09-14       Impact factor: 3.686

Review 2.  A functional approach to transcriptome profiling: linking gene expression patterns to metabolites that matter.

Authors:  Cindi A Hoover; Marc Slattery; Adam G Marsh
Journal:  Mar Biotechnol (NY)       Date:  2007-05-01       Impact factor: 3.619

3.  Potentiation of the Fosmidomycin analogue FR 900098 with substituted 2-oxazolines against Francisella novicida.

Authors:  Matthew D Stephens; Nisakorn Yodsanit; Christian Melander
Journal:  Medchemcomm       Date:  2016-07-27       Impact factor: 3.597

Review 4.  The Mycobacterium tuberculosis MEP (2C-methyl-d-erythritol 4-phosphate) pathway as a new drug target.

Authors:  Hyungjin Eoh; Patrick J Brennan; Dean C Crick
Journal:  Tuberculosis (Edinb)       Date:  2008-09-14       Impact factor: 3.131

Review 5.  Targeting Metalloenzymes for Therapeutic Intervention.

Authors:  Allie Y Chen; Rebecca N Adamek; Benjamin L Dick; Cy V Credille; Christine N Morrison; Seth M Cohen
Journal:  Chem Rev       Date:  2018-09-07       Impact factor: 60.622

6.  Structure-guided design and biosynthesis of a novel FR-900098 analogue as a potent Plasmodium falciparum 1-deoxy-D-xylulose-5-phosphate reductoisomerase (Dxr) inhibitor.

Authors:  Ryan E Cobb; Brian Bae; Zhi Li; Matthew A DeSieno; Satish K Nair; Huimin Zhao
Journal:  Chem Commun (Camb)       Date:  2015-02-14       Impact factor: 6.222

7.  Crystal structure of Brucella abortus deoxyxylulose-5-phosphate reductoisomerase-like (DRL) enzyme involved in isoprenoid biosynthesis.

Authors:  Jordi Pérez-Gil; Bárbara M Calisto; Christoph Behrendt; Thomas Kurz; Ignacio Fita; Manuel Rodríguez-Concepción
Journal:  J Biol Chem       Date:  2012-03-22       Impact factor: 5.157

8.  Inhibition Studies on Enzymes Involved in Isoprenoid Biosynthesis: Focus on Two Potential Drug Targets: DXR and IDI-2 Enzymes.

Authors:  Jérôme de Ruyck; Johan Wouters; C Dale Poulter
Journal:  Curr Enzym Inhib       Date:  2011-07

9.  New N-acetyltransferase fold in the structure and mechanism of the phosphonate biosynthetic enzyme FrbF.

Authors:  Brian Bae; Ryan E Cobb; Matthew A DeSieno; Huimin Zhao; Satish K Nair
Journal:  J Biol Chem       Date:  2011-08-24       Impact factor: 5.157

10.  Functional genetic analysis of the Plasmodium falciparum deoxyxylulose 5-phosphate reductoisomerase gene.

Authors:  Audrey R Odom; Wesley C Van Voorhis
Journal:  Mol Biochem Parasitol       Date:  2009-12-16       Impact factor: 1.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.